{
  "Figure": "nihms862967_page16_391.jpg",
  "Figure_title": "Figure 1.  In vivo efficacy of taselisib in the KPL-4 PIK3CA-mutant breast cancer xenograft model.  Taselisib was dosed orally and daily at the doses indicated for 21 days as indicated by  treatment period (Rx). Control tumor bearing mice were treated with 0.5% methylcellulose/ 0.2% Tween-80 (vehicle). Tumor volumes were measured and calculated as described in  Materials and Methods. "
}